Comparison of different phenotypic methods detecting extended spectrum beta-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii strains;Pseudomonas aeruginosa ve Acinetobacter baumannii suşlarιnda genişlemiş spektrumlu beta-laktamaz varlιǧιnιn saptanmasιnda farklι fenotipik yöntemlerin karşιlaştιrιlmasι

Mikrobiyoloji Bulteni

Volumn 39, Issue 3, 2005, Pages 265-272

  Zarakolu, Pinar ^a   Metan, Gökhan ^b   Hasçelik, Gülşen ^a   Akova, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Acinetobacter baumannii; Combined disk; Double disk synergy; E test; Extended spectrum beta lactamases (ESBL); Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; ENZYME INHIBITOR;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; MICROBIOLOGICAL EXAMINATION; PHENOTYPE; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; SENSITIVITY AND SPECIFICITY;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORINS; CLAVULANIC ACID; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; SENSITIVITY AND SPECIFICITY;

EID: 33846407288     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bradford PA: Extended spectrum beta-lactamases in the 21th century: Characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001, 14: 933-951.
2. Palucha A, Mikiewicz B, Gniadkowski M: Diversification of Escherichia coli expressing an SHV-type extended-spectrum beta-lactamase (ESBL) during a hospital outbreak: emergence of an ESBL-hyperproducing strain resistant to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1999, 43: 393-396.
3. Weiner J, Quinn JP, Bradford PA, et al: Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999, 281: 517-523.
4. Sardan YC, Zarakolu P, Altun B, Yildirim A, Yildirim G, Hasçelik G, Uzun O: A cluster of nosocomial Klebsiella oxytoca bloodstream infections in a university hospital. Infect Control Hosp Epidemiol 2004, 25: 878-882.
5. Poirel L, Weldhagen GF, De Champs C, Nordmann P: A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002, 49: 561-565.
6. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P: Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003, 41: 3542-3547.
7. Vahapoglu H, Ozturk R, Tansel O, et al: Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997, 41: 2265-2269.
8. Vahapoglu H, Coskunkan F, Tansel O, et al: Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol 2001, 50: 642-645.
9. Sturenburg E, Mack D: Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003, 47: 273-295.
10. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved Standard M2-A7, 7th ed. 2000. NCCLS, Wayne, Pennsylvania.
11. Livermore DM, Brown DF: Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001, 48 (Suppl 1): 59-64.
12. M'Zali FH, Chanawong A, Kerr KG, Birkenhead D, Hawkey PM: Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the MAST DD test, the double disc and the E-test ESBL. J Antimicrob Chemother 2000, 45: 881-885.
13. Bush K: New beta-lactamases in Gram negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001, 32: 1085-1089.
14. Livermore DM: Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8: 557-584.
15. Essack SY: Laboratory detection of extended-spectrum beta-lactamases (ESBLs)-the need for a reliable, reproducible method. Diagn Microbial Infect Dis 2000, 37: 293-295.
16. Thomson KS: Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Inf Dis 2001, 7: 333-336.
17. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A5. 2004. Wayne, Pennsylvania.
18. White DJ, Sands RL: Storage of bacteria at -76 degrees C. Med Lab Sci 1985, 42: 289-290.
19. Unal S, Masterton R, Goossens H: Bacteraemia in Europe antimicrobial susceptibility data from the MYSTIC surveillance programme. Int J Antimicrob Agents 2004, 23: 155-163.
20. Mimoz O, Elhelali N, Léotard S, et al: Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase producing strain of Pseudomonas aeruginosa. J Antimicrob Chemother 1999, 44: 91-97.
21. Weldhagen GF, Prinsloo A: Molecular detection of GES-2 extended spectrum beta-lactamase producing Pseudomonas aeruginosa in Pretoria, South Africa. Int J Antimicrob Agents 2004, 24: 35-38.
22. Aktas Z, Poirel L, Salcioglu M, et al: PER-1- and OXA-10-like beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey. Clin Microbiol Infect 2005, 11: 193-198.
23. De Champs C, Poirel L, Bonnet R, et al: Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002, 46: 3031-3034.
24. Bert F, Ould-Hocine Z, Juvin M, et al: Evaluation of the Osiris Expert System for identification of beta-lactam phenotypes in isolates of Pseudomonas aeruginosa. J Clin Microbiol 2003, 41: 3712-3718.
25. Gottlieb T, Wolfson C: Comparison of the MICs of cefepime for extended- spectrum beta-lactamase producing and non-extended spectrum beta-lactamase producing strains of Enterobacter cloacae. J Antimicrob Chemother 2000, 46: 330-331.
26. Hancock REW, Bellido W: Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992, 29 (Suppl A): 1-6.
27. Stürenburg E, Sobottka I, Noor D, Laufs R, Mack D: Evaluation of a new cefepime-clavulanate ESBL E-test to detect extended spectrum beta-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 2004, 54: 134-138.
28. Weldhagen GF, Poirel L, Nordmann P: Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003, 47: 2385-2392.
29. Mugnier P, Dubrous P, Casin I, Arlet G, Gollatz E: A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996, 40: 2488-2493.
30. Danel F, Hall LCM, Gur D, Livermore DM: OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999, 43: 1362-1366.
31. Bert F, Branger C, Lambert-Zechovsky N: Identification of PSE and OXA beta-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 2002, 50: 11-18.
32. Kang CI, Kim SH, Park WB, et al: Bloodstream infections caused by antibiotic resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49: 760-766.
33. Micek ST, Lloyd AE, Rtichie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49: 1306-1311.